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Background: Chronic Kidney Disease (CKD) is a major non-communicable chronic disease that is associated with
adverse clinical and economic outcomes. Passive surveillance systems are likely to improve efforts for prevention of
chronic kidney disease (CKD) and inform national service planning. This study was conducted to determine the
overall prevalence of CKD in the Irish health system, assess period trends and explore patterns of variation as part
of a novel surveillance initiative.
Methods: We identified 207, 336 adult patients, age 18 and over, with serum creatinine measurements recorded
from a provincial database between 2005-2011 in the Northwest of Ireland. Estimated glomerular filtration rates
(eGFR) were determined using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation from
standardized creatinine measurements and the presence of CKD was defined as eGFR <60 ml/min per 1.73 m2. Age
and sex-specific prevalence estimates were determined for each group while generalized estimating equations
(GEE) and multivariable logistic regression were used to explore associations using adjusted odds ratios (AOR) and
95% confidence intervals (95% CI).
Results: The prevalence of CKD in the health system was 11.8% (95% CI 11.8-12.1); 10.9% in men (10.7-11.1) and
12.6% in women (12.4-12.8). This corresponded to a detection rate of 4.5% (5.1% in women and 3.9% in men). The
prevalence of CKD was significantly higher in women than in men (12.6% versus 10.9%, P < 0.001), older age groups,
and among patients with a history of Acute Kidney Injury (AKI) than without (45.2% versus 10.7%, P < 0.0001).
Multivariable analysis identified advancing age, female gender, location of medical supervision, county of
residence, and AKI as significant determinants of prevalence.
Conclusion: The prevalence of CKD in the Irish health system is 11.8% corresponding to a detection rate of 4.5%
in the general population. Demographic, geographic factors and acute kidney injury episodes are important
determinants of disease burden. Passive surveillance of CKD is both feasible and desirable within the Irish health
system, and offers huge opportunities for targeted prevention programmes and improved clinical outcomes.
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Chronic Kidney disease (CKD) has emerged as a major
public health epidemic, which contributes substantially
to adverse clinical and economic outcomes [1-4]. It is
estimated that at least 1 in 10 individuals of the general
population have some degree of kidney impairment and
have substantially increased risk for death, even prior
to developing end-stage kidney disease (ESKD) [1-3].
For those who develop ESKD, the outcomes are even
poorer with an average life expectancy of <5 years
[5-8]. For many patients, CKD is largely an asymptom-
atic disease that can progress silently without treat-
ment for many patients unless it is actively screened
for by medical providers. Early detection of CKD and
the application of specific interventions provide major
opportunities to prevent and delay progression [9]. Tar-
geted surveillance systems are now seen as essential plat-
forms to combat the rising tide of CKD and its attendant
sequelae [10-15].
Although the epidemiology of CKD is well characterized
in many countries, there remain several unanswered ques-
tions. The extent to which CKD is captured within exist-
ing health systems has not been fully explored and is a
crucial starting point for most surveillance programmes.
A detailed exploration of differences in CKD prevalence
by geography is an equally important goal to uncover pos-
sible differences in risk factor burden and disparities in
clinical care. Acute Kidney Injury (AKI) is a common ill-
ness, with reported prevalence of up to 7.1% of all hospital
admissions [16]. Emerging evidence suggests that AKI
events accelerate the risk of developing CKD [17], yet its
impact on CKD within an Irish population has not yet
been studied. Finally, the location of medical supervision
where cases are first identified by physician providers is an
important consideration as it provides opportunities for
early initiation of prevention strategies. In Ireland, the lack
of robust surveillance systems for tracking and monitoring
CKD burden and outcomes has been identified a major
deficiency. The 2007 Survey of Lifestyle, Attitudes and
Nutrition (SLÁN), a nationally representative sample of all
subjects’ age >45, has provided the first national estimate
of CKD prevalence in Ireland with a figure of 11.6% [18].
This important study, however; was restricted to sub-
jects >45 years, unable to assess longitudinal trends, and
did not measure the extent to which CKD was captured
within the Irish health system.
To overcome these deficits, we have initiated a programme
for CKD surveillance in Ireland to improve our knowledge.
The major objectives of this study were to 1) describe the
prevalence of CKD within the health system, 2) explore
patterns of variation according to demographic and geo-
graphic characteristics, and location of medical supervision,
and to 3) assess the impact of AKI on disease prevalence.
These objectives were pursued by creating a passive CKDsurveillance system using routinely collected data from a
regional health system.
Methods
We conducted a retrospective observational study of all
patients with measured serum creatinine concentrations
from a regional laboratory information system in the
Northwest of Ireland. The laboratory system captured all
blood chemistries from inpatient admissions and out-
patient attendances at two regional hospitals and as well
as primary care practices across the region. Ethical ap-
proval for the study was granted by the Ethics Commit-
tees at Sligo and Letterkenny General Hospitals.
Sample
From January 1st 2005 to 31st December 2011, a total of
278,630 patients underwent 69,594,271 laboratory test
evaluations in the Northwest region. The current ana-
lysis was restricted to adult participants, 18 years of age
or older with recorded serum creatinine measurements
and non-missing data on sex (n = 206, 729). Creatinine
tests administered during periods of dialysis and AKI
were excluded. Estimated glomerular filtration rate (eGFR)
in ml/min per 1.73 m2 was determined for patients using
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) and the Modification of Diet in Renal Disease
Study (MDRD) [19,20].
Data collection
Patient and laboratory information systems captured
data on demographic factors, county of residence, loca-
tion of supervision, primary location of blood draw, and
dialysis indicator variables. Serum creatinine was mea-
sured using the modified kinetic Jaffe method and creatin-
ine values were calibrated to be traceable to an isotope
dilution mass spectrometry (IDMS) reference measure-
ment procedure to ensure standardization. Chronic Kidney
Disease was defined according to the Kidney Disease Dialy-
sis Quality Outcome Initiative (KDOQI) guidelines based
on eGFR measurements expressed in ml/min/1.73 m2 and
categorized as Stage 3 (eGFR <30-59), Stage 4 (eGFR 15-
29 and Stage 5 (eGFR <15). Higher categories of eGFR
were categorized as normal (eGFR >90) or mildly reduced
(eGFR 60- 89) [21]. The presence of Acute Kidney Injury
(AKI) was defined by the Kidney Disease Improving Global
Outcomes (KDIGO) criteria [16]. The location of medical
supervision was defined as the location where the serum
creatinine test was first ordered by the supervising health
professional and categorised as; inpatient location (IP),
outpatient department (OP), general practice (GP), and
outside community facility (OS). The identification of
these locations was considered important as we surmised
that testing rates for CKD would vary by clinical setting.
County of residence for each patient was extracted from
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sify patients by geography. The principal counties served
by the regional database included county Donegal, Sligo
and Leitrim and these accounted for 95.5% of all labora-
tory testing.
Estimation of Chronic Kidney Disease prevalence
The prevalence of CKD in the health system for a calendar
year was defined as percentage of patients with a mean
eGFR <60 ml/min/1.73 m2 with corresponding 95% Confi-
dence Intervals (CI). For patients with more than one
serum creatinine value in a calendar year, the correspond-
ing eGFR levels were estimated and the means of all eGFR
values were calculated. Creatinine test results that satisfied
criteria for the diagnosis of AKI based on the KDIGO cri-
teria were excluded from prevalence estimation. The
prevalence of detectable CKD within the Northwest popu-
lation was derived using national census data for 2006 and
2011 with projected estimates for the intervening years
[22]. The prevalence of detectable CKD in the population,
stratified by age and sex categories, was defined as the ratio
of the number of patients with a mean eGFR <60 ml/min/
1.73 m2 (numerator), restricted to that group of patients
known to reside in either Leitrim, Donegal or Sligo, to the
combined population of Sligo, Leitrim and Donegal for a
calendar year (denominator).
Statistical analysis
Generalized Estimating Equations (GEE) and multivari-
able logistic regression models were fitted to explore the
associations of demographic, clinical and geographic fac-
tors with CKD prevalence. In each model, the response
variable was eGFR <60 ml/min/1.73 m2. The explanatory
variables included age modeled in categories, sex, county
of residence, location of medical supervision, presence
and frequency of AKI and calendar year. A final multi-
variable model was constructed to explore the relative
contribution of all factors with CKD prevalence. A work-
ing independence correlation structure was assumed when
fitting the model so that the final parameter estimates for
each model agree with the corresponding logistic regres-
sion. The sandwich estimator was used to adjust the
standard errors of the estimated coefficients to account
for the longitudinal aspect of the design. The associations
of explanatory factors with CKD presence were repre-
sented by adjusted odds-ratios (AOR) and 95% CI. Wald
statistics from the corresponding generalized estimating
equations were used to test for the significance of these
associations. Finally Joinpoint regression analysis [23] was
used to assess prevalence trends in health system and the
population. The Joinpoint model used allowed for hetero-
skedastic standard errors in the prevalence estimates and
an autoregressive dependence structure to reflect the fact
that the same patients may contribute to the prevalenceestimates in successive years. Several sensitivity analyses
were conducted to explore the robustness of our observa-
tions. First, we compared prevalence estimates using both
the MDRD and CKD-EPI equations. Second, we also con-
sidered the minimum, median and maximum eGFR values
over a calendar year as additional summary measures for
a particular patient in estimating of prevalence. The final
analytic dataset was constructed using R software and
statistical analysis was performed using SAS v9.3 and Join-
point Regression Program [24].Results
Baseline characteristics of the population
The characteristics of patients within the Northwest
Heath System are described in Table 1. The mean age was
54.2 (±18) years, 54.1% were female and 41.3% were over
the age of 60 years. The majority of patients were resident
in the counties of Donegal (53.5%), Sligo (29.6%) and Lei-
trim (12.4%), with smaller proportion of patients (4.51%)
living in other counties (see Table 1 for details). Testing
for kidney function was ordered by general practitioners
(GP) for 67.8% of patients and by emergency physicians
(EP) for 15% of patients. The average creatinine concen-
tration (μmol/L), and estimated GFR (ml/min/1.73 m2)
for the entire population were 80.1 (±28.8) and 86.8
(±22.7) respectively. Overall, 3.2% of patients within the
health system had evidence of AKI, and this was signifi-
cantly higher for patients with CKD than those without
(12.6% versus 2.0% respectively, P <0.001).Prevalence of CKD in the Irish Health System
The overall prevalence of CKD was 11.8% (95% CI 11.8-
12.1%) using the CKD-EPI equation and was signifi-
cantly lower than estimates from the MDRD equation
(13.5%, 95% CI 13.3-13.6) as shown in Table 2. To sim-
plify exposition, all of the subsequently quoted preva-
lence estimates will be based on the CKD-EPI equation.
Among those with CKD, the majority were classified as
having Stage 3 (90.1%), with 8.0% and 1.9% classified as
Stage 4 and Stage 5 respectively. The prevalence of CKD
was significantly higher in women than in men (12.6% vs
10.9%, P <0.0001) and increased substantially with advan-
cing age. Among the major counties, Leitrim had the high-
est prevalence (12.8%) while the prevalence in Donegal and
Sligo were slightly lower at 12.0% and 11.3%. The preva-
lence estimates for all other counties with at least 400 or
more patients are provided in Figure 1. The Additional file 1:
Figure S1 provides additional information on the preva-
lence of CKD among participant counties along with the
corresponding age distributions. The prevalence of CKD
in the health system varied significantly by the presence
and frequency of AKI. Compared to patients without a his-
tory of AKI, those with AKI experienced over a four-fold
Table 1 Characteristics of patients in the Irish health system1
Patient characteristics Entire cohort 2005 2006 2007 2008 2009 2010 2011
Count (n) 206,729 64,674 71,118 75,956 79,300 81,338 85,200 89,679
Demographics
Age X SDð Þ 54.2 (18.2) 54.4 (18.4) 54 (18.4) 53.9 (18.4) 54.1 (18.2) 54.2 (18.2) 54.4 (18.1) 54.4 (18.1)
Sex
% Women 54.1 54.6 54.0 54.3 54.4 54.2 53.6 53.9
% Men 45.9 45.4 46.0 45.7 45.6 45.8 46.4 46.1
County of Residence (%)
Donegal 53.5 52.9 52.3 53.2 53.6 53.9 54.0 54.5
Sligo 29.6 30.5 30.8 29.9 29.6 29.5 29.0 28.4
Leitrim 12.4 12.0 12.2 12.4 12.3 12.3 12.6 12.6
Other County5 4.51 4.60 4.69 4.51 4.42 4.33 4.47 4.56
Location of Supervision (%)2
Outpatient Department 7.1 5.3 4.5 4 7.8 8.7 8.7 9.5
General Practitioner 67.8 64.3 67.4 68.2 67.7 67.6 69.3 69.4
Emergency Room 15.1 17.3 16.3 16 14.4 14.5 14.1 14
Inpatient Location 5.0 7.5 6.5 6.5 4.7 4.2 3.3 3.1
Outside facility 5.0 5.6 5.2 5.3 5.5 5.0 4.7 4.0
Kidney Function (X SDð Þ)
Serum creatinine count 1,388,625 171,922 183,565 199,533 205,493 203,938 204,204 219,970
Serum creatinine (μmol/L) 80.1 (28.8) 82.5 (33.4) 81 (31) 79.7 (29.2) 78.6 (28) 80 (27.3) 79.4 (26.6) 80.1 (26.8)
Mean eGFR (ml/min/1.73 m2)3 86.8 (22.7) 84.8 (23.2) 86.4 (23.1) 87.5 (22.9) 88.2 (22.7) 86.7 (22.5) 87.2 (22.3) 86.5 (22.4)
Minimum GFR (ml/min/1.73 m2)3
(ml/min/1.73 m)2
84.2 (23.9) 82.0 (24.5) 83.7 (24.4) 84.8 (24.3) 85.6 (24) 84.0 (23.7) 84.7 (23.4) 84.0 (23.5)
Maximum eGFR (ml/min.73 m2)3 89.2 (22.4) 87.4 (22.9) 88.9 (22.8) 90.0 (22.5) 90.6 (22.3) 89.1 (22.2) 89.4 (22) 88.8 (22.1)
Serum Electrolytes (X SDð Þ)
Sodium (mmol/L) 140.2 ( 2.8) 140.1 (2.9) 140.3 (2.8) 140.2 (2.8) 140.3 (2.8) 139.9 (2.7) 140.2 (2.7) 140.5 (2.6)
Potassium (mmol/L) 4.5 ( 0.5) 4.4 (0.5) 4.5 (0.5) 4.5 (0.5) 4.5 (0.5) 4.5 (0.5) 4.5 (0.5) 4.5 (0.5)
Urea (mmol/L) 6.2 ( 2.7) 6.1 (2.8) 6.1 (2.7) 6.1 (2.7) 6.3 (2.7) 6.3 (2.7) 6.3 (2.6) 6.1 (2.6)
Calcium (mmol/L) 2.3 ( 0.1) 2.4 (0.1) 2.3 (0.1) 2.3 (0.1) 2.3 (0.1) 2.3 (0.1) 2.3 (0.1) 2.3 (0.1)
Phosphorous (mmol/L) 1.1 ( 0.2) 1.1 (0.2) 1.1 (0.2) 1.2 (0.2) 1.1 (0.2) 1.1 (0.2) 1.1 (0.2) 1.1 (0.2)
Hematology Variables
Haemoglobin (g/dl) 13.8 (1.6) 13.8 (1.6) 13.9 (1.6) 13.9 (1.6) 13.7 (1.6) 13.7 (1.6) 13.7 (1.6) 13.8 (1.6)
Serum ferritin ng/ml 130.9 (286.4) 127.3 (295.1) 124.0 (341.6) 127.8 (236.8) 128.6 (228) 135.8 (396.3) 132.7 (223.2) 137.2 (254.2)
Other Laboratory Variables
Serum uric acid (UA) (μmol/L) 355.7(109.5) 369.4(119.6) 352.7 (111.8) 346.8 (106.5) 352.2 (106.5) 355.7 (108.9) 354.5 (106.5) 362.9 (108.9)
Acute Kidney Injury4
% with AKI 3.2 3.3 3.5 3.4 3.2 3.1 2.8 3.0
% of AKI in patients with no CKD 2.0 1.9 2.2 2.11 1.99 2.0 1.8 1.9
% of AKI in patients with CKD 12.6 12.0 12.9 13.68 13.41 12.2 12.0 12.1
1Values are reported as % or mean with standard deviation.
2Location of Supervision is defined as the type of facility where the first test was carried out.
3eGFR CKD-EPI: Glomerular filtration rate (ml/min per 1.73 m2) was based on the Chronic Kidney Disease Collaborative (CKD-EPI) [21].
4The occurrence of acute kidney injury (AKI) was based on the KDIGO Definition [16].
5The list of counties and their relative contributions were as follows.
Donegal (n = 101,587), Sligo (n = 50,264), Leitrim (n = 22,356), Galway (n = 329), Derry (n = 418), Cavan (n = 1,251), Tyrone (n = 319), Roscommon (n = 2,403), Mayo
(n = 5,546), Fermanagh (n = 158), Longford (n = 229), Westmeath (n = 15). Information on home address was unrecorded for 21,854 patients.
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Table 2 Prevalence of chronic kidney disease (95% confidence intervals) in the Irish health system
CKD-EPI equation1 95% CI MDRD equation2 95% CI
Overall Prevalence (%) 11.8 (11.8-12.1) 13.5 (13.3-13.6)
By Stage (%)
Stage 3 CKD 10.7 (10.6-10.9) 12.5 (12.4-12.7)
Stage 4 CKD 0.95 (0.94-0.99) 0.83 (0.79-0.87)
Stage 5 CKD (No dialysis) 0.15 (0.14-0.17) 0.14 (0.12-0.15)
Stage 5 CKD (Dialysis only)3 0.07 (0.06-0.09) 0.07 (0.06-0.09)
By Age group (%)4
18-39 0.45 (0.39-0.51) 0.93 (0.9-1.0)
40-59 2.24 (2.13-2.35) 4.55 (4.4-4.7)
60-80 18.9 (18.6-19.3) 22.0 (21.6-22.3)
> 80 55.7 (54.9-56.4)* 52.4 (51.6-53.1)
By Gender (%)4
Women 12.6 (12.4-12.8) 15.0 (14.8-15.2)
Men 10.9 (10.7-11.1)* 11.7 (11.5-11.9)
By County (%)4
Donegal 12.0 (11.7-12.2) 13.5 (13.3-13.8)
Sligo 11.3 (11.0-11.6) 13.1 (12.7-13.4)
Leitrim 12.8 (12.3-13.3) 14.6 (14.1-15.1)
All other counties6 11.6 (11.1-12.0)* 13.2 (12.8,13.7)
By Acute Kidney Injury (%)5
No AKI 10.7 (10.6-10.9) 12.5 (12.3-12.6)
History of AKI 45.2 (44.3-46.1)* 45.5 (44.6-46.3)
By Number of AKI Episodes (%)
0 10.9 (10.7-11) 12.4 (12.3-12.6)
1 39.1 (38.2-40) 39.5 (38.6-40.5)
2 54.8 (52.9-56.8) 54.8 (52.8-56.7)
3 64.8 (61.4-68.1) 63.4 (59.9-66.8)
4 64.1 (58.4-69.3) 65.4 (59.8-70.6)
≥5 88.7 (85.9-91.0)* 88.9 (86.1-91.1)
1eGFR CKD-EPI: Glomerular filtration rate (ml/min per 1.73 m2) was based on the Chronic Kidney Disease Collaborative [21].
2eGFR: Glomerular filtration rate (ml/min per 1.73 m2) was based on the Modification of Diet in Renal Disease Study Equation (MDRD) Equation [20].
3Patients undergoing dialysis treatment were identified from the Northwest Kidney Disease Register.
4Prevalence of CKD was based on the patients having stage 3 CKD or higher category.
5The occurrence of acute kidney injury (AKI) was based on the KDIGO Definition [16].
*P < 0.001 for significant differences between groups.
6Individual county prevalence, and associated 95% CIs, for counties aggregated into ‘Other counties’ were: Galway: 4% (2.4%, 6.6%), Derry 11% (8%,15%), Cavan:
13.5 (11.6%,15.8%) , Tyrone: 11.3% (8.2%, 15.3%), Roscommon: 10.4% (9.1%, 11.8%), Mayo: 11.7% (10.8%, 12.8%), Fermanagh 12.8% (8.5%, 18.8%), Longford: 15.8%
(10.1%, 23.9%), Unknown county , 11.5% (11.0%,12.0%), Westmeath: 6.3% (0.9%, 33.5%). Note that as shown in Additional file 1: Figure S1, the age distribution of
patients in Galway is significantly younger than those from other counties.
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spectively, P <0.001).
Prevalence of detectable CKD in the Irish population
Based on census data, we estimated the prevalence of detect-
able CKD in the population to be 4.5% (95% CI 4.46-4.59%)
as shown in Table 3. The prevalence of detectable CKD
was significantly higher in women than men (5.1% versus
3.9%) and increased exponentially with advancing age. To
facilitate comparison with national estimates derived fromthe 2007 Survey of Lifestyle, Attitudes and Nutrition
(SLÁN), we recalculated prevalence but restricted to sub-
jects age 45 and older (Table 4). The population prevalence
restricted to this age group was 9.7% (95% CI 9.6-9.9%) and
was higher in women than men (11.0 vs 8.4%, P < 0.001).
Period trends in CKD prevalence in the Irish Health
System and General Population
Period trends in prevalence of CKD within the health
system are illustrated in Table 5. The prevalence peaked
Figure 1 Prevalence of CKD and 95% confidence intervals by county in the health system. 1The health system included all patients with
measured creatinine concentrations age 18 or older. 2We excluded counties where numbers of patients included were less than 400 patients.
Unknown = unknown county of origin.
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eral, the prevalence fell significantly from 2005 to 2008
and remained constant thereafter. This change in trend
was statistically significant (P = 0.007) when tested using
Joinpoint regression analysis. This pattern was similar for
men and women throughout all years, although the preva-
lence was significantly higher in women than in men. Within
age groups, the prevalence of CKD remained relativelyTable 3 Prevalence of detectable CKD (95% confidence interv
CKD-EPI equation2
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1Population estimates were determined for 2006 and 2011 using the Irish Populatio
2eGFR CKD-EPI: Glomerular filtration rate (ml/min per 1.73 m2) was based on the Ch
3eGFR: Glomerular filtration rate (ml/min per 1.73 m2) was based on the Modificatio
*P < 0.001 for differences in percentages between groups.constant over the 7-year period with the lowest prevalence
among the 18-39 year olds and the highest prevalence in
the >80 year olds. Comparison of CKD prevalence within
the health system and corresponding general population for
men and women are also illustrated in Figure 2. The preva-
lence of detectable CKD in the general population fell
significantly from 4.5 to 4.2% between 2005 and 2008
(P = 0.018), and increased thereafter to 5.0 in 2011 (Figure 2).als) by category in the Irish population1












n census, restricted to individuals age ≥18 years of age.
ronic Kidney Disease Collaborative [21].
n of Diet in Renal Disease Study Equation (MDRD) Equation [20].
Table 4 Prevalence of detectable CKD (95% confidence
intervals) restricted to patients over 45
CKD-EPI 95% CI MDRD 95% CI
Prevalence based on North West Regional Database (%)1
Overall 9.7 (9.6-9.9) 10.9 (10.8-11.1)
Women 11.0 (10.8-11.2) 12.9 (12.7-13.1)
Men 8.4 (8.2-8.6)* 8.9 (8.7-9.1)
Prevalence based on SLAN Survey (%)2
Overall 11.6 (9.0-14.2) 15.7 (12.7,18.7)
Women3 11.2 (7.3,15.2)
Men 12.0 (9.0,14.2)
1Population estimates were determined for 2006 and 2011 using the Irish
Population censes, restricted to individuals age ≥18 years of age.
2Based on a criterion of eGFR ≤60 ml/min/1.73 m2.
3Gender stratified prevalence estimated, based on the MDRD equation were
not reported in Browne et al. [18]. *P<0.001 for comparison with women.
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System
Table 6 describes the relationship of demographic, clinical
and geographic factors with CKD prevalence within the
health system. In this series of analysis, we explored asso-
ciations of each listed covariate with CKD presence in
demographic–adjusted and fully adjusted models. The
prevalence of CKD correlated with advancing age and fe-
male gender. CKD was more likely to be detected when
screening in an outpatient department (Adjusted odds ra-
tio (AOR) 1.50, 95% CI 1.44-1.57) or community health
facilities (AOR 1.09, 1.03-1.15) and less likely to found
when screening in emergency departments (AOR, 0.90,
0.87-0.94) or inpatient wards (AOR 0.87, 0.83-0.91). Com-
pared to patients entering the health system in 2005, those
that were tested in subsequent years were less likely to
have CKD, P < 0.001. The likelihood of CKD varied sig-
nificantly by county of residence. Compared to patients
resident in Sligo (referent group, AOR = 1.00), patients
resident in Donegal (AOR = 1.07, 1.02-1.11) and Leitrim
(AOR = 1.09, 1.03-1.16) were significantly more likely to
have CKD. The relationship between AKI and CKD was
significant and substantial. Compared to patients with-
out any prior episode of AKI during the calendar period,
each episode of AKI conferred an increasing likelihood
of CKD. For example, patients who had incurred three
AKI events experienced a 7.4 fold higher likelihood of
CKD compared with those who had no prior AKI event.
The C-statistic of the model was 0.86 indicating excel-
lent discrimination.
Discussion
In this surveillance study, we sought to describe the preva-
lence and variation of CKD in the Irish health system. We
found that the overall prevalence of CKD in the health
system was 11.8% (approximately 1 in 8 patients), higher
in women than men, and increased substantially withadvancing age. There was evidence for regional vari-
ation in CKD prevalence that was not explained by dif-
ferences in age or sex distributions. We also found that
most CKD could be easily identified from designated
locations within the health system; the inpatient ward,
outpatient clinic and the community hospital. Given
the emerging interest in the AKI-CKD link [17,25,26],
we demonstrated that among patients with a prior his-
tory of AKI, the prevalence of CKD was almost 50%,
and that the likelihood of CKD increased with increas-
ing frequency of AKI events. At the population level,
we showed that the prevalence of detectable CKD in
the region was 4.5%, and that when restricted to pa-
tients age 45 and older, our estimate of CKD preva-
lence was similar to that derived from the nationally
representative SLAN survey.
The present study provides compelling evidence that
passive surveillance of CKD within a regional health sys-
tem is achievable and provides accurate and essential in-
formation on disease burden and its determinants that
are necessary for service planning and resource alloca-
tion. Recognising the global challenge of CKD and its
adverse complications, there is an urgent need for well-
developed surveillance systems to capture CKD and track
clinical outcomes within a countries health system [14].
Through extraction of data from the regional laboratory
system and administrative systems we were able to esti-
mate the prevalence of CKD, identify important correlates
and assess prevalent trends from 2005-2011. This initia-
tive is the first of its kind in Ireland to support systematic
surveillance of CKD and provides the foundation stone
for a national surveillance programme.
The current study is the largest conducted in Ireland
and provides a reliable estimate of CKD prevalence in the
Irish health system. Our sample of 206, 729 patients, in-
cluded all adults within the northwest health system with
at least one measured creatinine concentration. Our preva-
lence estimate of 11.8% was lower than that reported by
Glynn et al who found a prevalence of 16.7% CKD among
2,602 primary care patients age >50 years and Anderson
et al who reported an even higher prevalence of 20%
among elderly patients with established cardiovascular
disease [27,28]. However, unlike Glynn et al, we did not
restrict our sample to high-risk older age groups. It is pos-
sible that differences in CKD prevalence reflect differences
in definitions of CKD, the choice of sampling frame, the
measure used for its determination, and the size of the de-
nominator. Systematic reviews of prevalence studies have
found substantial variation in estimates ranging from 0.6-
42.6% [29]. To facilitate comparisons with national data,
we estimated the population prevalence of detectable
CKD in the northwest region by substituting the population
in the health system with that of the general population as
our new denominator. The derived population estimate of
Table 5 Period trends in CKD prevalence in the health system1
Entire cohort 2005 2006 2007 2008 2009 2010 2011
Count (n) 206,729 64,674 71,118 75,956 79,300 81,338 85,200 89,679
Overall Prevalence 11.9 13.8 12.4 11.6 10.9 11.8 11.4 11.8
By stage
3 10.73 12.4 11.2 10.5 9.8 10.7 10.3 10.7
4 0.95 1.18 1.09 0.96 0.87 0.87 0.83 0.88
5 0.15 0.26 0.18 0.16 0.15 0.13 0.11 0.12
By Gender
Women 12.7 14.9 13.3 12.3 11.6 12.4 12.0 12.3
Men 10.9 12.5 11.4 10.7 10.0 10.9 10.3 10.9
By Age group
18-39 0.4 0.6 0.5 0.5 0.4 0.5 0.3 0.4
40-59 2.2 2.9 2.5 2.2 2.1 2.2 2.0 2.0
60-80 18.9 22.8 20.4 18.8 17.1 18.6 17.3 18.3
> 80 55.6 58.6 56.5 54.4 52.5 56.3 55.5 56.0
By age group (females)
18-39 0.35 0.48 0.36 0.32 0.33 0.41 0.33 0.25
40-59 2.18 2.8 2.5 2.2 2.0 2.0 1.9 2.0
60-80 20.40 24.9 22.1 20.2 18.5 20.2 18.6 19.6
> 80 57.63 60.7 57.9 56.6 54.5 58.2 57.6 58.3
By age group (males)
18-39 0.6 0.6 0.6 0.8 0.6 0.6 0.4 0.6
40-59 2.3 2.9 2.5 2.2 2.2 2.4 2.1 2.1
60-80 17.4 20.6 18.7 17.4 15.7 17.0 16.1 17.0
> 80 52.4 55.3 54.1 50.8 49.4 53.3 52.2 52.4
By Geographic origin
Sligo 11.3 13.6 12.0 11.1 10.6 10.7 10.5 11.0
Donegal 12.0 13.5 12.4 11.7 10.8 12.2 11.5 12.0
Leitrim 12.8 15.4 13.5 12.1 12.0 12.8 12.3 12.4
All other counties 11.6 13.9 12.5 11.4 10.7 10.8 10.3 11.1
By Acute Kidney Injury2
No AKI 10.7 12.6 11.2 10.4 9.8 10.7 10.3 10.7
With AKI 45.2 50.8 45.5 45.6 44.3 42.4 44.3 44.6
1Estimated Glomerular filtration rate (ml/min per 1.73 m2) was determined by the CKD-EPI formula [21].
2The occurrence of acute kidney injury (AKI) was based on the KDIGO Definition [16].
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other countries, but remarkably similar to that generated
from Scottish and UK national data [1,15,30]. Moreover,
when we compared our data with national data from the
SLAN survey using similar definitions (i.e. limited to age
45 and over), our estimate of 9.7% was slightly lower but
nonetheless similar to the 11.6% that reported by Browne
et al [18]. These data would suggest that a large propor-
tion of CKD within the general population is already
captured within the Irish health system.
The availability of serial measurements on serum
creatinine concentrations over time allowed us a uniqueopportunity to capture the presence and frequency of AKI
in the health system and explore association with CKD
presence. When modeled as a binary variable or in cat-
egories, AKI was significantly and independently associ-
ated with CKD. Furthermore, our multivariable model
demonstrated a steep rise in gradient of risk with each epi-
sode of AKI. These observations support the increasing
body of evidence that link AKI with risk of CKD [17,25,26].
Chawla et al found higher rates of disease progression
to stage 4 CKD among AKI survivors in a population of
US veterans [17]. Similarly, studies by Ishani et al and
Thaker et al have identified strong associations between
Figure 2 Prevalence of detectable CKD in the adult General Population1 and the Health System2 for men and women from 2005-2011.
1The denominator for the population prevalence was based on Irish census data for 2006 and 2011 with projected estimates for the intervening
years, and restricted to adults age 18 and over. 2The health system included all patients with measured creatinine concentrations age 18 or older.
Creatinine test results that satisfied criteria for the diagnosis of AKI based on the KDIGO criteria were excluded [16].
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verse populations [25,26]. The evidence thus far would
suggest that the frequency and severity of AKI in the
health system has a direct impact on the burden of CKD
in the population. One might therefore hypothesize that
preventive efforts to reduce the frequency of AKI, in com-
bination with improved management of the usual CKD
risk factors such as diabetes, may lead to a stabilization of
CKD prevalence and eventually a possible decline.
Our study is the first to shed new light on the frequency
of testing for CKD in the Irish health system, and the rela-
tionship of geographic location and location of supervision
with CKD. Overall, the majority of blood tests for assess-
ment of kidney function were ordered by general practi-
tioners (67.8%) followed by emergency room physicians
(15.1%). As in many national health systems, the primary
care provider plays a pivotal role in chronic disease man-
agement both in screening for and monitoring of CKD in
the health system [31,32]. There were 1, 388, 625 creatin-
ine tests ordered for 206, 729 patients, giving an average
of 6.7 tests per patient. Based on these data, one could
infer that each patient had on average 6.7 opportunities to
detect the presence of impaired kidney function. CKD was
more likely to be present if blood tests were ordered at
the outpatient department, an inpatient admission, outside
community hospital and to a lesser degree the emergency
room compared to general practice. Blood tests ordered
through the outpatient department had the strongest asso-
ciations with CKD. These data reflect the fact that patients
who have their serum creatinine measured are likely tointeract with the health system at different locations, each
providing an opportunity to screen for and monitor CKD.
In this analysis, we also found differences in the preva-
lence of CKD by county of residence. Although the crude
prevalence did not vary substantially, we did identify dif-
ferences when adjustments were made for age and sex.
Differences in the testing rate, underlying risk factors and
their treatment may be responsible for these differences.
There are limitations to the present study. Our defin-
ition of CKD was based on creatinine- derived GFR esti-
mating equations alone and would have benefited from
inclusion of data on albuminuria in order to detect earl-
ier stages of disease. We also acknowledge that our study
lacked data on major risk factors for CKD including dia-
betes and hypertension which would have strengthened
our analysis. Notwithstanding these deficits, our study
had several major strengths. First, our estimate of kidney
function was based on original standardised creatinine
concentrations from which we derived estimated eGFR
values using the CKD-EPI and MDRD equations and
were thus not reliant on administrative claims data for
CKD diagnosis. Second, we had complete access to the
regional laboratory information system in the Northwest
Region which included clinical data from all primary
care and secondary care providers providing excellent
generalizability. Third, our study was conducted over a
7-year period and we were able to provide information
on period trends. Fourth, the size of the population was
extremely large thereby allowing us generate very precise
estimates of CKD across representative subgroups.
Table 6 Factors associated with CKD prevalence in the Irish health system1
Variable Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Adjusted demographics2 Adjusted all factors3
Demographic factors
Age group (years)
18-39 1.00 (referent) 1.00 (referent)
40-59 5.0 (4.32,5.78) <.0001 5.14 (4.46,5.92) <.0001
60-79 50.27 (43.74,57.79) <.0001 51.17 (44.68,58.59) <.0001
> = 80 265.74 (230.83,305.88) <.0001 260.66 (227.26,298.93) <.0001
Sex
Women (vs. men) 1.17 (1.13,1.22) <.0001 1.21 (1.17,1.26) <.0001
Location of supervision
General Practice (GP) 1.00 (referent) 1.00 (referent)
Emergency room vs. GP 1.04 (1.01,1.08) 0.01 0.90 (0.87,0.94) <.0001
Inpatient location vs. GP 1.17 (1.12,1.23) < .0001 0.87 (0.83,0.91) <.0001
Outpatient Department vs. GP 1.64 (1.58,1.72) < .0001 1.50 (1.44,1.57) <.0001
Outside facility vs. GP 1.13 (1.06,1.19) < .0001 1.09 (1.03,1.15) 0.004
Calendar Year
2005 1.00 (referent) 1.00 (referent)
2006 vs. 2005 0.88 (0.85,0.90) < .0001 0.87 (0.84,0.89) <.0001
2007 vs. 2005 0.79 (0.76,0.81) < .0001 0.79 (0.76,0.81) <.0001
2008 vs. 2005 0.72 (0.69,0.74) < .0001 0.71 (0.68,0.73) <.0001
2009 vs. 2005 0.80 (0.77,0.82) < .0001 0.78 (0.76,0.81) <.0001
2010 vs. 2005 0.74 (0.72,0.76) < .0001 0.73 (0.71,0.76) <.0001
2011 vs. 2005 0.78 (0.76,0.80) < .0001 0.77 (0.74,0.79) <.0001
# Acute Kidney Injury4 episodes
0 1.00 (referent) 1.00 (referent)
1 vs. 0 2.36 (2.24,2.48) < .0001 2.41 (2.29,2.54) <.0001
2 vs. 0 4.11 (3.71,4.54) < .0001 4.20 (3.79,4.65) <.0001
3 vs. 0 7.19 (5.90,8.77) < .0001 7.39 (6.06,9.02) <.0001
4 vs. 0 9.44 (6.74,13.1) < .0001 9.70 (6.94,13.55) <.0001
5 vs. 0 120.0 (79.7,180.6) < .0001 102.56 (69.15,152.09) <.0001
County of Residence
Sligo 1.00 (referent) 1.00 (referent)
Donegal vs. Sligo 1.05 (1.01,1.10) 0.02 1.07 (1.02,1.11) 0.0035
Leitrim vs. Sligo 1.08 (1.02,1.14) 0.01 1.09 (1.03,1.16) 0.0031
Other counties vs. Sligo 1.03 (0.97,1.09) 0.30 1.07 (1.01,1.13) 0.0244
Primary Hospital5
Letterkenny vs. Sligo6 1.00 (0.96,1.03) 0.88
1Estimated Glomerular filtration rate (ml/min per 1.73 m2) calculated by the eGFR CKD-EPI formula [21] was used to calculate prevalence.
2Adjusted for age, sex only.
3Adjusted for age, sex, provider location, calendar year, county of residence, acute kidney injury.
4The occurrence of acute kidney injury (AKI) was based on the KDIGO Definition [16].
5Primary hospital location was not included in the final multivariable model.
6Letterkenny General Hospital is located in county Donegal, while Sligo General Hospital is the primary hospital for the county of Sligo.
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The current study is the largest study to-date to describe
the prevalence of CKD in the Irish Health system andprovide comparisons with national data. It demonstrates
that the detection of CKD within the health system is
remarkably similar to percentages reported within the
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http://www.biomedcentral.com/1471-2369/15/185general Irish population. It highlights significant variation
in prevalence across representative groups and provides
compelling evidence that AKI is strongly linked with CKD
burden. Finally, while the burden of CKD has declined
from 2005-2008, our analysis suggests a more recent trend
of increasing growth which has important clinical and
economic consequences. This study is the first output of
National Kidney Disease Surveillance System in Ireland, a
programme that will serve as a major resource for track-
ing and monitoring kidney disease and outcomes in the
Irish health system.
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